Cetuximab (Erbitux®). This compound, available as Erbitux® (Merck Sereno), is a human–murine chimeric monoclonal antibody that competes to bind to the extracellular domain of EGFR and has been approved for the treatment of colorectal and head and neck cancer [620]. Here, EGFR is linked to head and neck cancer.